Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies
Summary
Now the Swiss pharmaceutical giant is looking to bolster its capabilities in liver and central nervous system (CNS) disorder gene therapies and it’s turning to Dyno Therapeutics to help. Gene therapies that have reached the market so far, such as Luxturna and Zolgensma, a Novartis (NYSE: NVS) treatment for spinal muscular atrophy, are delivered by engineered adeno-associated (AAV) viruses. The technology screens hundreds of thousands of capsids at one time, looking for desirable properties, such as its ability to target specific tissue, payload capacity, interactions with the immune system, deliverability, and manufacturing. Though the Roche alliance with Dyno calls for the startup to use its technology to design capsids for CNS and liver gene therapies, the companies aren’t specifying which diseases are covered by the pact. The structure of the deal is similar to alliances with Novartis (NYSE: NVS) and Sarepta Therapeutics (NASDAQ: SRPT) that Dyno unveiled in May, when the startup emerged from stealth.
Classifications
AskAI Classifications
LabelsLinked Companies
